BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12141739)

  • 1. Prophylactic vaccination against Lyme borreliosis for man and dogs and new strategies to treat established B. burgdorferi infections.
    Wallich R; Jahraus O; Simon MM
    Int J Med Microbiol; 2002 Jun; 291 Suppl 33():147-9. PubMed ID: 12141739
    [No Abstract]   [Full Text] [Related]  

  • 2. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
    Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
    Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lyme borreliosis--vaccines in the "pipeline"].
    Kramer M
    MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against Lyme borreliosis.
    Wahlberg P
    Ann Med; 1999 Aug; 31(4):233-5. PubMed ID: 10480752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More on diagnosis of canine borreliosis.
    Sonneborn-Turetsky JH
    J Am Vet Med Assoc; 1993 Dec; 203(11):1521-2. PubMed ID: 8288468
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.
    Fikrig E; Telford SR; Wallich R; Chen M; Lobet Y; Matuschka FR; Kimsey RB; Kantor FS; Barthold SW; Spielman A; Flavell RA
    J Exp Med; 1995 Jan; 181(1):215-21. PubMed ID: 7807004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
    Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
    J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
    Sigal LH
    J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease.
    Brunet LR; Katavolos P; Spielman A; Telford SR
    Med Vet Entomol; 1997 Apr; 11(2):198-200. PubMed ID: 9226653
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination as a modality to prevent Lyme disease. A status report.
    Wormser GP
    Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization against Lyme disease--an important first step.
    Steigbigel RT; Benach JL
    N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of OspA vaccination on Lyme disease serologic testing.
    Aguero-Rosenfeld ME; Roberge J; Carbonaro CA; Nowakowski J; Nadelman RB; Wormser GP
    J Clin Microbiol; 1999 Nov; 37(11):3718-21. PubMed ID: 10523583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.